Glenmark Pharmaceuticals is a worldwide pharmaceutical company based in Mumbai, India. The company is primarily focussed on the therapeutic segments of oncology, dermatology, and respiratory.
The market capitalisation of Glenmark Pharmaceuticals Limited, as of July 4, 2018, is a little over Rs.16,500 crore.
Company’s Wealth and Recent Performance
- For the fourth quarter of the financial year 2017-18, the company reported its consolidated revenue from operations to be at Rs.22,798 million. In contrast to the same quarter of the previous year, this figure is down by 7.22%.
- Similarly, for the year ended on March 31, 2018, Glenmark Pharma reported its consolidated income to be at Rs.91,030.7 million. Over the financial year 2016-17, this is a marginal decrease of 0.90%.
- Considering the net profit after tax for the March quarter, it was revealed to be at Rs.1,516.27 million. Just like the consolidated revenue, profit too has gone down when compared to the March quarter of the previous year. Similarly, for the FY2017-18, Glenmark Pharma’s net profit after tax came down to Rs.8,038.70 million from Rs.11,087.53.
- The Earnings per Share for the year was reported to be at Rs.28.49, in contrast to Rs.39.29 reported in the previous year.
- The company’s sales in India improved by 9% but its sales in Latin America and the United States were down by 21.51% and 13.32% respectively.
Glenmark Pharmaceuticals Limited Stock Trends in 2018
- On January 2, 2018, the opening price of Glenmark Pharma stock was Rs.593.10 on the National Stock Exchange. Over the course of next three weeks, the stock price rose steadily to cross the Rs.600 mark. In the same month, it reached a high of Rs.645.45 before coming down dramatically. The scrip ended the month at Rs.606.20.
- The price plummeted further in February on the back of a poor performance in the Q3 FY18. The company’s net profit for the quarter was down by more than 70% and as a result, the Glenmark Pharma share price suffered heavily. By the end of the first week of February, the scrip was back at its previous levels at Rs.570 - Rs.580. The share price went down further over the course of the month to close at Rs.544.55 on February 28.
- The month of March did not bring any relief to the investors. The stock price of Glenmark Pharmaceuticals continued to go down and the scrip ended the month at Rs.526.30. The price rose slightly in April but it wasn’t close to the levels witnessed by the stock at the start of the year. The closing price of Glenmark stock on April 30 was Rs.571.70.
- May turned out to be the most disappointing month for the investors. The stock continued to exhibit its bearish behaviour and on May 21, it reached its 52-week low at Rs.493.50 during an intraday session. In the final week, the prices recovered slightly to end the month at Rs.535.95. The month of June was a relatively better one for the investors as the scrip made up for its previous losses. The price rose steadily and on June 29, Glenmark Pharma stocks finished trading at Rs.583.05.
Glenmark Pharmaceuticals Limited Stock Trends in 2016 and 2017
- At the start of 2016, the share price of Glenmark Pharmaceuticals was at levels around Rs.930. In roughly three weeks, the stock lost a little over 10% to descend into the Rs.700 region. Through most of February, the shares were traded at levels varying from Rs.710 - Rs.750. In March, the share price rose once again to ascend into the Rs.800 territory, although in the second half, the price dropped once again.
- The stocks continued to go through their usual ups and downs in the second quarter of the year as well. In April, the price rose to cross the Rs.850 mark and the shares were traded at those levels for most of May as well. In early June, the share price of Glenmark Pharma dipped sharply to retreat back to their previous levels at Rs.770.
- Once again, the prices rose in July and the stocks recuperated their previous losses. The shares were changing hands in the Rs.800 region through most of July, August, and even September. Investors sentiments were high on the back of positive developments in the company. A final dividend of 200% was also announced in early August.
- In October, the shares ascended into the Rs.900 region. Unlike many stocks, things didn’t change a lot for Glenmark Pharma stocks after demonetisation in November. The prices dipped slightly and the stocks were traded at levels above Rs.880 for the remainder of the year. The stocks ended the year at Rs.888.45.
- 2017 started on a rather positive note for the investors as Glenmark Pharma shares started the year trading at Rs.888.80. In early February, the share price rose to enter the Rs.900 territory and the shares were traded at those levels till mid-March. Towards the end of March, the stock price dipped again and the shares retreated back to the Rs.880 level.
- Things didn’t change a lot in April. In May, Glenmark Pharma stock price took a sharp nosedive on the back of the company missing its estimates for the fourth quarter of the FY17. In just two weeks, the share price went down from Rs.861 to Rs.610, effectively shedding more than 20%. The scrip has since struggled to recover and achieve its previous levels.
- In July, the prices rose marginally driven by positive developments in the company. The share price of Glenmark Pharmaceuticals Limited crossed Rs.700, but only to shed all those gains immediately in the early August. The price continued to slide down over the remaining weeks of the year.
- A final dividend of 200% was announced in September but that didn’t do much to boost investors confidence. In October, the scrip entered the Rs.500 region on a couple of occasions during intraday trading sessions. By mid-November, the shares finally slipped into this territory and for the remainder of the year, Glenmark Pharma shares were traded at levels varying from Rs.530 - Rs.590. The closing price on December 29, 2017, was Rs.594.75.
Should you invest in Glenmark Pharmaceuticals Limited?
- For the year ended on March 31, 2018, the company’s income from operations and net profit reported a substantial decrease. Its revenues in regions like Latin America and the United States have suffered as well. In terms of the performance of the stock, the scrip has been on a bear run since May 2017.
- In the pharmaceutical sector, there are companies which are doing relatively better than Glenmark. At the same time, the company’s future prospects and medications may boost its numbers. Before investing in this stock, it is recommended that you do your own research.
Glenmark Pharmaceutical Limited is a global pharmaceutical company headquartered in Mumbai, India. It is one of the leading players in the new molecules segment in New Chemical Entity and New Biological Entity. The company sells its products in more than 80 countries, including the developed markets like the US and Western Europe. Glenmark Pharmaceuticals Limited has 17 manufacturing facilities and 5 established research and development centers.
History of the Company
Glenmark Pharmaceuticals was founded in 1977 by Late Mr. Gracias Saldanha. Two years later, the company entered the market with the launch of Candid Cream which turned out to be a huge success. Over the course of next couple of decades, the company forayed into different therapeutic segments. In 1999, the company established its first R&D centre in Maharashtra and in 2000, Glenmark Pharma listed its shares on the NSE and BSE. In 2001, the company diversified its operations and ventured into API (Active Pharmaceuticals Ingredients) manufacturing. That decade also saw Glenmark sealing its first licensing deal with Forest Laboratories. Eventually, the company expanded its operations into international markets, starting with the US in 2005.
Management of the Company
Mr. Glenn Saldanha - Chairman & Managing Director
Mr. Saldanha joined Glenmark Pharmaceuticals Limited in 1998 as Director. Three years later, he was appointed as the Managing Director & CEO. Under his leadership, Glenmark Pharmaceuticals became an organisation with revenues more than a billion dollars. He also oversaw the expansion of the company into the international markets, particularly in Latin America and the United States. He completed his graduation from Mumbai University and followed it with an MBA from the Leonard Stern School of Business, New York University.
Ms. Cherylann Pinto - Executive Director - Corporate Affairs
Ms. Pinto has been a part of Glenmark Pharmaceuticals Limited since 1999. She has been in the pharma industry for more than 26 years. Prior to her appointment in the organisation, she worked as the Managing Director of a pharmaceutical company she had founded for 10 years. At Glenmark Pharma Limited, she heads various crucial divisions like human resource, information technology, corporate communications, administration, and corporate social responsibility.
Mr. V.S. Mani - Global Chief Financial Officer
Mr. Mani serves as the Global CFO of Glenmark Pharmaceuticals Limited and is also an executive member of the Board of Directors. He oversees the important worldwide finance operations of the company such as accounting, reporting, treasury, and taxation. He has been a part of the finance industry for more than 25 years and has worked in various important segments like treasury, taxation,
accounting, risk management, investor relations, and financial analysis & planning. He is also a certified Chartered Accountant.
Glenmark Pharmaceuticals Limited Listings in NSE, BSE, and Indices
Glenmark Pharma shares are available for trading to the general public on the National Stock Exchange of India Limited and the Stock Exchange, Mumbai. The codes used to distinguish the company’s stock on these exchanges are as follows:
- NSE Code: GLENMARK
- BSE Code: 532296
- ISIN: INE935A01035
- Sector: Pharmaceuticals
As for the stock market indices, the company is a part of the following:
- NIFTY 200
- NIFTY 500
- NIFTY Midcap 150
- NIFTY Quality 30
- S&P BSE 100
- S&P BSE 200
- S&P BSE AllCap
Glenmark Pharmaceuticals Limited
B/2, Mahalaxmi Chambers
22, Bhulabhai Desai Road
Mumbai - 400-026, Maharashtra
Contact number: +91-22-4018-9999
Stocks vs. Mutual Funds: here's what we recommend
Stock market investments require a lot of research and knowledge. They do not generally offer any tax benefits and are regarded as high-risk investments. Hence,it is crucial to have a diversified portfolio. At Bankbazaar, we encourage our readers to invest on mutual funds.It doesn't require a lot of knowledge and equity linked mutual fund schemes offer tax benefits. Additionally, since mutual funds comprise stocks from multiple companies, they help in building a diversified portfolio.
The contents of this post/blog does not constitute financial or other professional advice nor does it imply in any manner a principal-agent relationship, and is not a professional advice on a specific financial matter.